RNXT News & Events

RenovoRx announces the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Voll brings more than three decades of financial leadership experience to RenovoRx. He has served as Chief Financial Officer for multiple publicly traded technology companies .

RenovoRx announced that new clinical data will be presented at the 2026 Society of Interventional Oncology, SIO, Annual Scientific Meeting on February 6, 2026. The clinical data abstract entitled, "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors," was led by Christopher Laing, MD of Sutter Health in California. The study explores a simplified method for measuring intra-arterial pressure during procedures that use the TAMP therapy platform enabled by the RenovoCath catheter. The findings in this study demonstrate that a simplified, external pressure transducer provides reliable and reproducible intra-arterial pressure measurements during TAMP procedures, with strong correlation to intravascular pressure wire measurements in a porcine model.

RenovoRx announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company's RenovoCath patented FDA-cleared drug-delivery device into oncology treatment programs. The Company's TAMP therapy platform, enabled by the RenovoCath device, is designed to deliver chemotherapy near the tumor site, potentially enhancing therapeutic effectiveness and minimizing the systemic side effects commonly associated with traditional intravenous chemotherapy administration. The number of active commercial cancer centers which are eligible to order and use RenovoCath has increased from five in September 2025 to nine currently and growing with the addition of City of Hope Cancer Center in Duarte, California and Moffitt Cancer Center in Tampa, Florida.